Home Stock

Stock Research: SCI Pharmtech,

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

SCI Pharmtech,

TSEC:4119 TW0004119003
74
  • Value
    47
  • Growth
    92
  • Safety
    Safety
    58
  • Combined
    84
  • Sentiment
    36
  • 360° View
    360° View
    74
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

SCI Pharmtech, Inc. is a Taiwan-based company focused on manufacturing and selling Active Pharmaceutical Ingredients (APIs). The company operates in the pharmaceutical industry, producing APIs, API intermediates, and special chemicals. It distributes its products in Taiwan, Europe, the Americas, and other parts of Asia. In the last fiscal year, the company had a market cap of $254 million, profits of $13 million, and revenue of $46 million. The number of employees is not available.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 74 (better than 74% compared with alternatives), overall professional sentiment and financial characteristics for the stock SCI Pharmtech, are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for SCI Pharmtech,. The consolidated Value Rank has an attractive rank of 58, which means that the share price of SCI Pharmtech, is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 58% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 92, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 36. Professional investors are more confident in 64% other stocks. Worryingly, the company has risky financing, with a Safety rank of 47. This means 53% of comparable companies have a safer financing structure than SCI Pharmtech,. ...read more

more
Country Taiwan
Industry Pharmaceuticals
Size X-Small
Website sci-pharmtech.com.tw
Index
FTSE Taiwan
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
58 22 16 35
Growth
92 74 97 83
Safety
Safety
47 27 51 88
Sentiment
36 8 20 37
360° View
360° View
74 7 36 85
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
14 12 25 28
Opinions Change
50 50 50 50
Pro Holdings
n/a 32 38 55
Market Pulse
1 1 1 n/a
Sentiment
36 8 20 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
58 22 16 35
Growth
92 74 97 83
Safety Safety
47 27 51 88
Combined
84 27 56 86
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
74 14 42 20
Price vs. Earnings (P/E)
19 18 9 20
Price vs. Book (P/B)
59 31 29 48
Dividend Yield
68 44 21 75
Value
58 22 16 35
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
90 94 49 83
Profit Growth
90 70 100 23
Capital Growth
90 18 95 84
Stock Returns
12 56 71 65
Growth
92 74 97 83
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
55 41 55 96
Refinancing
22 24 21 35
Liquidity
65 49 78 100
Safety Safety
47 27 51 88

Similar Stocks

Discover high‑ranked alternatives to SCI Pharmtech, and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Tsumura

TSE:4540
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Sumitomo Forestry

TSE:1911
Country: Japan
Industry: Homebuilding
Size: X-Large
Full Stock Analysis

Hisamitsu Pharmaceutical

TSE:4530
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis
OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.